Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2
diabetes patients switched from biphasic human insulin 30: Results from the
Indonesian cohort of the A1chieve study
a University
of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia
b Division of Endocrine Metabolic, Department of Internal Medicine, H Adam Malik Hospital, Medan, Indonesia c
b Division of Endocrine Metabolic, Department of Internal Medicine, H Adam Malik Hospital, Medan, Indonesia c
Abstract
Aim: To
evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30)
in Indonesian type 2 diabetes patients switched from biphasic human insulin 30
(BHI 30) as a sub-analysis of the A1chieve study. Methods: Clinical
safety and effectiveness over 24 weeks was evaluated in Indonesian patients who
switched from BHI 30 to BIAsp 30 at the discretion of their physician. Results:
A total of 244 patients with mean age ± SD 55.6±9.5 years, BMI 24.6±3.8kg/m2,
and mean diabetes duration 7.8±5.7 years were included. The mean pre-study BHI
30 dose was 0.56±0.25 IU/kg and the baseline BIAsp 30 dose was 0.60±0.26U/kg
titrated up to 0.65±0.25 U/kg by Week 24. No serious adverse drug reactions
were reported throughout the study. Overall hypoglycaemia decreased from 2.18
to 0.06 events/patient-year with a significant decrease in the proportion of
patients affected (p < 0.0001). No nocturnal or major hypoglycaemia was
reported at Week 24. HbA1c improved from 8.8±1.2% at baseline
to 7.3±0.8% at Week 24. A total of 45 patients achieved HbA1c <7.0%
as compared to 5 patients with HbA1c <7.0% at baseline. FPG
and PPPG improved significantly after 24 weeks (p < 0.001). Quality of life
was positively impacted (change in visual analogue scores, 3.0±11.6 points, p
< 0.001). Conclusion: Switching from BHI 30 to BIAsp 30 in this Indonesian
cohort was well-tolerated and improved glycaemic control with a decreased risk
of hypoglycaemia. © 2013 Elsevier Ireland Ltd.
Full Text :
Tidak ada komentar:
Posting Komentar